Comparison · NCT01704755-sae
ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks vs ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks vs ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks: serious adverse events. Trial comparisons, record NCT01704755-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01704755-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0625 | 0.0369 | 0.104 | wilson | |
| Risk in group 2 | 0.0407 | 0.0199 | 0.0816 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0218 | -0.0265 | 0.0682 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.54 | 0.627 | 3.76 | log | |
| Odds ratio, group 1 over group 2 | 1.57 | 0.613 | 4.03 | log | |
| Number needed to harm, for one more participant with a serious adverse event on ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks than on ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | 45.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if \<75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 12 weeks | 13 | 208 | EG000 |
| Group 2 | ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | ABT-450/r/ABT-267 (150/100/25 mg once daily) and ABT-333 (250 mg twice daily), plus weight-based ribavirin (RBV; 1,000 mg/day if \<75 kg or 1,200 mg/day if ≥75 kg, divided twice daily) for 24 weeks | 7 | 172 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse events were collected from the time of study drug administration until 30 days after the last dose, 16 weeks for the 12-week treatment group and 28 weeks for the 24-week treatment group.
Source ClinicalTrials.gov
Trial
- Title
A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis
- NCT number
- NCT01704755
- Phases
- PHASE3
- Conditions
- Chronic Hepatitis C Infection, Compensated Cirrhosis
- Interventions
- ABT-450/r/ABT-267, ABT-333, Ribavirin (RBV)
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Results first posted
- 2015-01-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01704755?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01704755-sae